Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
RESEARCH AND DEVELOPMENT SERVICES BA230121 TITLED SELF ASSEMBLING VACCINE PLATFORM is a federal Unrestricted award for Army Med Res Acq Activity held by Hexamer Therapeutics Inc. Estimated value $3.9M ($3.9M obligated). Current period of performance ends Mar 31, 2027. Last award drew 1 bidder. Place of performance: PULLMAN WA. Related solicitation HT942523SBAA1.
RESEARCH AND DEVELOPMENT SERVICES BA230121 TITLED SELF ASSEMBLING VACCINE PLATFORM
Recompete timing
PublicCurrent PoP ends Mar 31, 2027 (185 days remaining). Agencies typically plan 12–18 months ahead — at 6.1 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT942523C0078? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordHexamer Therapeutics Inc — $3.9M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942523C0078?
HT942523C0078 (Research and development services) is a Army Med Res Acq Activity award with a potential value of $3.9M, currently held by Hexamer Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT9425-23-C-0078?
HT9425-23-C-0078 is the dashed form of PIID HT942523C0078 (Research and development services), held by Hexamer Therapeutics Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT942523C0078?
Army Med Res Acq Activity awarded HT942523C0078 to Hexamer Therapeutics Inc (potential $3.9M).
Who is the incumbent on HT942523C0078?
Hexamer Therapeutics Inc is the incumbent with $3.9M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Mar 31, 2027.
When does Hexamer Therapeutics Inc’s HT942523C0078 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT942523C0078? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.